S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:AERI

Aerie Pharmaceuticals - AERI Stock Forecast, Price & News

$11.57
+0.48 (+4.33%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.15
$11.83
50-Day Range
$5.68
$11.64
52-Week Range
$4.81
$17.21
Volume
492,830 shs
Average Volume
751,192 shs
Market Capitalization
$571.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.50

Aerie Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
77.2% Upside
$20.50 Price Target
Short Interest
Healthy
6.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.97
Upright™ Environmental Score
News Sentiment
0.88mentions of Aerie Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.97) to ($1.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

438th out of 1,117 stocks

Biological Products, Except Diagnostic Industry

64th out of 175 stocks

AERI stock logo

About Aerie Pharmaceuticals (NASDAQ:AERI) Stock

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Aerie Pharmaceuticals Stock Down 4.7 %

Shares of Aerie Pharmaceuticals stock opened at $11.09 on Friday. Aerie Pharmaceuticals has a twelve month low of $4.81 and a twelve month high of $17.21. The firm's 50-day moving average price is $7.51 and its 200 day moving average price is $7.53.

Aerie Pharmaceuticals (NASDAQ:AERI - Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.20. During the same period in the previous year, the business posted ($0.67) earnings per share. As a group, analysts anticipate that Aerie Pharmaceuticals will post -1.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AERI. Citigroup lifted their target price on shares of Aerie Pharmaceuticals to $14.00 in a report on Tuesday. StockNews.com raised Aerie Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, June 28th.

Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AERI Stock News Headlines

Aerie Pharmaceuticals Q2 2022 Earnings Preview
See More Headlines
Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AERI Company Calendar

Last Earnings
8/04/2022
Today
8/12/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AERI
Employees
376
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.50
High Stock Price Forecast
$29.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+77.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-74,810,000.00
Pretax Margin
-23.24%

Debt

Sales & Book Value

Annual Sales
$194.13 million
Book Value
($2.86) per share

Miscellaneous

Free Float
45,061,000
Market Cap
$571.10 million
Optionable
Optionable
Beta
0.35

Key Executives

  • Mr. Raj Kannan (Age 58)
    CEO, Principal Financial Officer & Director
    Comp: $753.49k
  • Dr. Casey C. Kopczynski Ph.D. (Age 61)
    Co-Founder, Chief Innovation Officer & Head of Research and External Innovation
    Comp: $685.06k
  • Mr. John W. LaRocca Esq. (Age 57)
    Gen. Counsel & Sec.
    Comp: $676.62k
  • Mr. Peter F. Lang (Age 50)
    Chief Financial Officer
  • Dr. Michelle Senchyna Ph.D.
    Head of Clinical Devel. & Operations
  • Mr. Jeffrey M. Calabrese CPA (Age 55)
    VP of Fin. & Principal Accounting Officer
  • Ms. Carolyn McAuliffe
    Sr. Director of Communications
  • Ms. Wanda Francies
    Head of HR
  • Mr. Marvin J. Garrett (Age 71)
    Head of Regulatory Affairs & Quality Assurance
  • Mr. Craig R. Skenes
    Head of Bus. Devel.













AERI Stock - Frequently Asked Questions

Should I buy or sell Aerie Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AERI shares.
View AERI analyst ratings
or view top-rated stocks.

What is Aerie Pharmaceuticals' stock price forecast for 2022?

2 analysts have issued twelve-month price targets for Aerie Pharmaceuticals' shares. Their AERI share price forecasts range from $14.00 to $29.00. On average, they expect the company's stock price to reach $20.50 in the next year. This suggests a possible upside of 78.1% from the stock's current price.
View analysts price targets for AERI
or view top-rated stocks among Wall Street analysts.

How have AERI shares performed in 2022?

Aerie Pharmaceuticals' stock was trading at $7.02 at the start of the year. Since then, AERI stock has increased by 64.0% and is now trading at $11.51.
View the best growth stocks for 2022 here
.

When is Aerie Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AERI earnings forecast
.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its earnings results on Thursday, August, 4th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.20. During the same period in the prior year, the firm earned ($0.67) EPS.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (3.79%), Pinnacle Associates Ltd. (2.13%), Deutsche Bank AG (2.03%), Walleye Capital LLC (1.30%), FMR LLC (1.18%) and Granite Investment Partners LLC (0.96%). Insiders that own company stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends
.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $11.51.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $568.13 million and generates $194.13 million in revenue each year. The company earns $-74,810,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

The company employs 376 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for the company is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at abavishi@aeriepharma.com, or via fax at 949-526-8787.

This page (NASDAQ:AERI) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.